Addex Therapeutics Dividend
Dividend criteria checks 0/6
Addex Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
Industry average yield | 1.9% |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Earnings per share | -US$0.12 |
Dividend yield forecast | 0% |
Recent dividend updates
No updates
Recent updates
Addex, Indivior expand team up to develop therapies for substance use disorders
Aug 15Addex stock falls 11% amid $4.2M equity financing with Armistice
Jul 22Addex Therapeutics CEO Tim Dyer - Emerging Drugs For Central Nervous System (Video)
Oct 21Addex, Janssen initiate Phase 2 study of ADX71149 for epilepsy
Jun 07Addex Therapeutics reports Q1 results
May 05Addex drops 23% after pricing share offering
Jan 07Addex Therapeutics files to sell $10M of ADS
Dec 14Addex Therapeutics reports Q3 results
Nov 03Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if ADXN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ADXN's dividend payments have been increasing.
Dividend Yield vs Market
Addex Therapeutics Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (ADXN) | n/a |
Market Bottom 25% (US) | 1.4% |
Market Top 25% (US) | 4.4% |
Industry Average (Biotechs) | 1.9% |
Analyst forecast (ADXN) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate ADXN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ADXN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate ADXN's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ADXN has not reported any payouts.